This page shows the latest trial failures news and features for those working in and with pharma, biotech and healthcare.
PR022 did not show the desired effect in this trial,” said Alex Martin, the biotech’s CEO. ... considerably after the twin trial failures.
Regulatory reviews have started for Pfizer’s non-small cell lung cancer drug dacomitinib on both sides of the Atlantic, four years after a pair of trial failures left its future ... Dacomitinib missed its objectives in two phase III trials reported in
easy”. For its pharmaceuticals business the ‘downs’ included several late-stage trial failures towards the end of the year. ... Among them were a 7, 000 patient study of Xarelto in secondary stroke, a combination trial of Eylea and a drug-device
The EPOCH trial enrolled patients with established mild-to-moderate Alzheimer symptoms and was due to generate primary results later this year and complete fully in 2019. ... verubecestat. Merck (known as MSD outside the US and Canada) is currently
In essence, it involves sifting through thousands of 'industry episodes' such as launches, trial results, acquisitions and failures. ... The latest trial results from Amgen point out how its model is trying to create clear space from statins.
Much of the pharma industry's efforts in Alzheimer's have been directed at the amyloid plaques seen in the brains of patients – resulting in a string of trial failures. ... This approach has earlier failures too, however, with casualties including
More from news
Approximately 5 fully matching, plus 25 partially matching documents found.
major trial failures meaning the company was looking unlikely to fill the void created by patent expiries of key drugs.
Smaller entities such as Isu Abxis are listed companies whose stock prices and financial stability are especially vulnerable to trial failures. ... Some companies already have their biobetter pipelines in clinical trial stage.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
a series of clinical trial failures leading to the departure of AZ's previous CEO Brennan in April, 2012.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
However, the learnings from these ‘failures’ have paved the way for the robust pipeline of treatments that could potentially be coming to market in the next five years. ... A recent article by BLH Consultant David Cooney explored the bleak
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...